A study to compare additional treatment with Subconjunctival and Topical Bevacizumab (a drug known to reduce recurrence in various studies) combined with Pterygium surgery versus Pterygium surgery alone on recurrence of pterygium : A multi centric trial
Not Applicable
- Conditions
- Health Condition 1: null- Patients of Pterygium who meet the inclusion criteria and give their consent for trial
- Registration Number
- CTRI/2018/07/014812
- Lead Sponsor
- Office of DGAFMS Ministry of Defence
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Primary Pterygium extending >2 mm into cornea
Exclusion Criteria
ï??Previous limbal surgery/recurrent pterygium
ï??Ocular surface disease
ï??Any ocular infection
ï??Autoimmune disorders
ï??Pregnancy
ï??Systemic contraindications for bevacizumab â?? recent history of following (in last 6 months)
oMyocardial infarction
oStroke
oPulmonary embolism
oDeep Vein Thrombosis
oAny other thromboembolic condition
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence rateTimepoint: 3 months, 6 months, 9 months and 1 year
- Secondary Outcome Measures
Name Time Method Adverse eventsTimepoint: 3 months, 6 months, 9 months and 1 year